Why 2020 could be a make-or-break year for Novavax
November 08, 2019 at 15:04 PM EST
A new year will bring phase 3 trial results for Novavax's flu vaccine — and the company's got a lot riding on them.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|